Hospital General Universitario De Albacete — Clinical Trial Site

55 Registered trials

27 Currently recruiting

Organisation

Hospital General Universitario De Albacete

Location

Albacete, Spain

Identifier

ORG-100045775

Address

Calle Hermanos Falco 37, 02006, Spain

Departments

#2319:servicio de neurología
7213: Neurology
Allergology
Anestesia
Cardiolgy
CARDIOLOGY
Clinical Haematology
ES049A: Hematología
Geriatria
Geriatrics
Hematología
Hematology
Intensive medicine
Medical Oncology
Medicina Interna
Neurología
Neurology
Neurology Department
Neurology Service
OFTALMOLOGIA
ONCOLOGIA
Oncology
Oncology Service
Pneumology
Servicio de Alergia
Servicio de hematología
Servicio de Neurología
Servicio de Oncología y Hematología Pediátricas

Clinical trials at this site (55)

Search interface

A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting

2024-513035-25-00 Psychosis associated with Alzheimer’s Disease 4 2025-07-11
Use of statins in patients with intracerebral hemorrhage Recruiting

2024-511465-11-00 Spontaneous lobar ICH 5 2024-11-20
Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting

2024-511959-18-01 Acute Pulmonary Embolism 5 2024-07-01
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting

2023-504865-21-00 Essential Thrombocythemia patients who have an inadequa 5 2024-04-15
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting

2022-502741-10-00 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearra 7 2024-01-26
Single antiplatelet treatment with Ticagrelor or Aspirin after Transcatheter Aortic Valve Implantation: multicenter randomized clinical tria… Recruiting

2023-509290-22-00 Severe Symptomatic Aortic Stenosis 6 2022-01-21
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
MULTICENTER, RANDOMIZED, BLIND AND CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY IN THE CORRECTION OF DEFICIT IN SUBJECTS WI… Ended

2024-514528-17-00 Severe vitamin D deficiency 6 2025-09-15
A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended

2024-514680-26-00 Agitation Associated with Alzheimer’s Dementia 4 2025-07-17
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with po… Ended

2024-517199-39-00 COGNITIVE IMPAIRMENT ASSOCIATED WITH POST-COVID-19 SYND 4 2025-03-19
LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended

2024-512676-36-00 Langerhans Cell Histiocytosis 10 2024-10-09
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea… Ended

2024-514630-21-00 HER2 positive (HER2+), Hormone Receptor positive (HR+) 4 2022-08-11
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509372-41-00 Multiple Sclerosis 5 2022-01-30
Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti… Ended

2024-516039-28-00 Spontaneous Coronary Artery Dissection. 6 2021-09-28
Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer (ABACUS-2) Ended

2024-510750-28-00 Tumours of the urothelial tract requiring surgery (T1 h 4 2021-06-18
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended

2024-516905-22-00 Multiple myeloma 5 2018-10-22
"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone… Ended

2024-515368-29-00 patients with node positive breast cancer who do not ha 5 2012-09-20